Publicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (14)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary

  4. Natural history and surgical outcomes of Rathke’s cleft cysts: a Spanish multicenter study

    Frontiers in Endocrinology, Vol. 15

  5. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Clinical Significance of T2-Weighted Sequence Intensity on Magnetic Resonance Imaging in Clinically Non-Functioning Pituitary Adenomas

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, Vol. 131, Núm. 12, pp. 631-638

  2. Executive summary of the consensus document on hypophysitis of the Neuroendocrinology Area of Knowledge of the Spanish Society of Endocrinology and Nutrition

    Endocrinologia, Diabetes y Nutricion, Vol. 70, pp. 116-125

  3. Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population

    The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202

2022

  1. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma

    Journal of Neuro-Oncology, Vol. 160, Núm. 2, pp. 351-359

  2. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain

    Frontiers in Endocrinology, Vol. 13

2021

  1. Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain

    Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936

  2. Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes

    Experimental and Clinical Endocrinology and Diabetes, Vol. 129, Núm. 4, pp. 309-313

2019

  1. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study

    Pituitary, Vol. 22, Núm. 2, pp. 137-145

2016

  1. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408